Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label multicenter study of HRS-1167 plus abiraterone acetate and prednisone in metastatic prostate cancer
CTR20244275Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of M9466, abiraterone and prednisone in prostate cancer (PCa), sponsored by Hengrui Therapeutics. Primary endpoints: Dose-limiting toxicity, Recommended Phase II dose and 1 more. Started Dec 2024; status: active.
02
Drugs
M9466abirateroneprednisone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20244275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244275.